Gene Therapy for Age-Related Macular Degeneration

Asia-Pacific Journal of Ophthalmology

Volumn 5, Issue 4, 2016, Pages 300-303

  Constable, Ian Jeffery ^a,b,c   Blumenkranz, Mark Scott ^d   Schwartz, Steven D ^e   Barone, Sam ^f   Lai, Chooi May ^c   Rakoczy, Elizabeth Piroska ^c  

^a LIONS EYE INSTITUTE   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY   (United States)

^f Avalanche Biotechnologies   (United States)

Author keywords

adeno associated virus; gene therapy; macular degeneration; sFlt

Indexed keywords

ANGIOGENESIS INHIBITOR; FLT1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENE VECTOR; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MALE; METABOLISM; PHASE 1 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; VITRECTOMY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAOCULAR; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VITRECTOMY; WET MACULAR DEGENERATION;

EID: 84984810433     PISSN: None     EISSN: 21620989     Source Type: Journal    
DOI: 10.1097/APO.0000000000000222     Document Type: Review

References (29)

1. Bainbridge JW Mehat MS Sundaram V Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med. 2015; 372: 1887-1897.
2. Bainbridge JW Smith AJ Barker SS Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008; 358: 2231-2239.
3. Barnard AR Groppe M MacLaren RE. Gene therapy for choroideremia using an adeno-associated viral (AAV) vector. Cold Spring Harb Perspect Med. 2014; 5: a017293.
4. Bennett J Ashtari M Wellman J AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012; 4: 120ra15.
5. Jacobson SG Cideciyan AV Ratnakaram R Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012; 130: 9-24.
6. Maclachlan TK Lukason M Collins M Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Mol Ther. 2011; 19: 326-334.
7. MacLaren RE Groppe M Barnard AR Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet. 2014; 383: 1129-1137.
8. Sahel JA Roska B. Gene therapy for blindness. Annu Rev Neurosci. 2013; 36: 467-488.
9. Martin DF Maguire MG Comparison of Age-related Macular Degeneration Treatments Trials Research Group Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119: 1388-1398.
10. Regillo CD Brown DM Abraham P Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008; 145: 239-248.
11. Brechner RJ Rosenfeld PJ Babish JD Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol. 2011; 151: 887.e1-895.e1.
12. Curtis LH Hammill BG Qualls LG Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am J Ophthalmol. 2012; 153: 1116.e1-1124.e1.
13. Lad EM Hammill BG Qualls LG Anti-VEGF treatment patterns for neovascular age-related macular degeneration among Medicare beneficiaries. Am J Ophthalmol. 2014; 158: 537.e2-543.e2.
14. Holekamp NM Liu Y Yeh WS Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014; 157: 825.e1-833.e1.
15. Day S Acquah K Lee PP Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol. 2011; 152: 1014-1020.
16. Kendall RL Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993; 90: 10705-10709.
17. Kendall RL Wang G Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996; 226: 324-328.
18. Lai YK Shen WY Brankov M Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 2002; 9: 804-813.
19. Lai CM Shen WY Brankov M Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther. 2005; 12: 659-668.
20. Provost N Le Meur G Weber M Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther. 2005; 11: 275-283.
21. Yin L Greenberg K Hunter JJ Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci. 2011; 52: 2775-2783.
22. Li Q Miller R Han PY Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis. 2008; 14: 1760-1769.
23. Bennett J Maguire AM Cideciyan AV Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci USA. 1999; 96: 9920-9925.
24. Lai CM Estcourt MJ Wikstrom M rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci. 2009; 50: 4279-4287.
25. Lai CM Estcourt MJ Wikstrom M rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Gene Ther. 2012; 19: 999-1009.
26. Rakoczy EP Lai CM Magno AL Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet. 2015; 386: 2395-2403.
27. Ho AC Busbee BG Regillo CD Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014; 121: 2181-2192.
28. Wiesmann C Fuh G Christinger HW Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 1997; 91: 695-704.
29. Heier JS Brown DM Chong V Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119: 2537-2548.